ABSCIENCES (EPA:AB) AB Science: The clinical development of masitinib in sickle cell disease is among the 19 winning projects under the sixth call for “Hospital-Inuversity Research in health (RHU)”
Transparency directive : regulatory news
27/11/2023 08:04
ABSCIENCES's latest news
13/03/2024 12:58
07/03/2024 15:20
06/03/2024 20:21
29/02/2024 11:49
26/02/2024 18:32
28/11/2023 19:22
27/11/2023 08:04
29/09/2023 19:49
18/09/2023 18:05
01/06/2023 18:01
Other stories
28/04/2024 18:40
28/04/2024 12:53
28/04/2024 15:17
28/04/2024 18:54
28/04/2024 16:25
28/04/2024 14:30
28/04/2024 18:42
28/04/2024 19:03
28/04/2024 13:36
28/04/2024 13:29
28/04/2024 12:42
28/04/2024 07:58
28/04/2024 03:13
27/04/2024 12:21
28/04/2024 13:30
28/04/2024 16:31
28/04/2024 17:36
28/04/2024 18:04
28/04/2024 08:02
28/04/2024 09:00
28/04/2024 15:14
28/04/2024 16:06
28/04/2024 06:29
28/04/2024 14:08
28/04/2024 17:32
28/04/2024 14:00
28/04/2024 18:04
28/04/2024 18:49
28/04/2024 17:31
28/04/2024 18:49
27/04/2024 14:00
28/04/2024 11:41
28/04/2024 09:42
27/04/2024 20:48
28/04/2024 12:18
28/04/2024 17:03
27/04/2024 13:51
27/04/2024 13:26